سامانه مدیریت نشریات علمی دانشگاه علوم پزشکی مشهد

Kao, Yung Hsiang. (1402). Rapid predictive dosimetry for Second Strike prescription based on whole body radioiodine kinetics in differentiated thyroid cancer. , 12(1), 37-42. doi: 10.22038/aojnmb.2023.72667.1507
Yung Hsiang Kao. "Rapid predictive dosimetry for Second Strike prescription based on whole body radioiodine kinetics in differentiated thyroid cancer". , 12, 1, 1402, 37-42. doi: 10.22038/aojnmb.2023.72667.1507
Kao, Yung Hsiang. (1402). 'Rapid predictive dosimetry for Second Strike prescription based on whole body radioiodine kinetics in differentiated thyroid cancer', , 12(1), pp. 37-42. doi: 10.22038/aojnmb.2023.72667.1507
Kao, Yung Hsiang. Rapid predictive dosimetry for Second Strike prescription based on whole body radioiodine kinetics in differentiated thyroid cancer. , 1402; 12(1): 37-42. doi: 10.22038/aojnmb.2023.72667.1507

Rapid predictive dosimetry for Second Strike prescription based on whole body radioiodine kinetics in differentiated thyroid cancer

Asia Oceania Journal of Nuclear Medicine and Biology
مقاله 6، دوره 12، شماره 1، فروردین 2024، صفحه 37-42    اصل مقاله (1.34 M)
نوع مقاله: Others
شناسه دیجیتال (DOI): 10.22038/aojnmb.2023.72667.1507
نویسنده
Yung Hsiang Kao*
Department of Nuclear Medicine, The Royal Melbourne Hospital, Victoria, Australia
چکیده
Objective(s): In systemic radionuclide therapy such as radioiodine (I-131) for differentiated thyroid cancer, post-therapy dosimetry is essential to verify pre-therapy predictions, which in turn informs the next treatment. However, post-therapy multi-time point dosimetry is resource intensive and unfeasible in many institutions. We devised a schema of rapid predictive dosimetry by circumventing post-First Strike multi-time point dosimetry with carefully assigned gestalt values of predicted kinetics to personalise the Second Strike prescription.
Methods: Verification is performed after the First Strike. Patient-specific time-activity curve is plotted from serial measurements of whole body exposure rates to obtain its decay constant; its inverse is the whole body Time Integrated Activity Coefficient (TIAC). The percentage of whole body TIAC attributed to blood is carefully assigned by gestalt based on population kinetics tabulated in Part 1, adjusted by any metastasis on I-131 whole body scintigraphy. Marrow absorbed dose is calculated by EANM formularism. Lung safety threshold at 48h post-therapy is linearly scaled by height, where the patient’s risk of lung radiotoxicity is revealed from the whole body time-activity curve value at 48h. Predictive prescription for the second I-131 fraction (Second Strike) is by careful gestalt assessment based on predicted kinetics, remaining marrow and lung tolerance, marrow dose rate constraint per fraction (0.265 Gy/h), local regulatory and facility requirements in relation to radiation protection. Tumour dosimetry is obviated under the assumption of severe tumour absorbed dose heterogeneity. The final prescription for the Second Strike is usually the lowest I-131 activity amongst all clinical, dosimetric and regulatory constraints.
Results: This schema is incorporated into a Predictive Calculator spreadsheet for rapid predictive dosimetry, and is freely available. Calculations may be completed within minutes to generate personalised predictive prescriptions, making it feasible for routine clinical implementation.
Conclusion: Our innovative schema of rapid verification and predictive dosimetry bridges the technological gap between empiric vs theranostic prescription to help institutions modernise. Its expeditious design makes this schema feasible to be integrated into the routine clinical workflow. Its predictive estimates provide invaluable dosimetric insight to inform the next I-131 fraction, allowing every prescription to be scientifically rationalised and personalised according to individual circumstances.
کلیدواژه‌ها
Radioiodine؛ Differentiated thyroid cancer؛ Dosimetry؛ Dose rate؛ Theranostics
سایر فایل های مرتبط با مقاله
مراجع
  1. Taprogge J, Abreu C, Yusuf S, Ainsworth G, Phillip RH, Gear JI, et al. The Role of Pretherapy Quantitative Imaging and Dosimetry in Radioiodine Therapy for Advanced Thyroid Cancer. J Nucl Med. 2023; 64(7):1125-1130.
  2. Mauguen A, Grewal RK, Augensen F, Abusamra M, Mahajan S, Jayaprakasam VS, et al. The use of single-timepoint images to link administered radioiodine activity (MBq) to a prescribed lesion radiation-absorbed dose (cGy): a regression-based prediction interval tool for the management of well-differentiated thyroid cancer patients. Eur J Nucl Med Mol Imaging. 2023; 50(10):2971-2983.
  3. Konijnenberg M, Herrmann K, Kobe C, Verburg F, Hindorf C, Hustinx R, et al. EANM position paper on article 56 of the Council Directive 2013/59/Euratom (basic safety standards) for nuclear medicine therapy. Eur J Nucl Med Mol Imaging. 2021; 48: 67-72.
  4. Kao Y H. First Strike personalized predictive radioiodine prescription for inoperable metastatic differentiated thyroid Asia Ocean J Nucl Med Biol. 2023; 11: 158-167.
  5. Kao YH. Yes, the Holy Gray exists. Learn from modern radioembolisation. Eur J Nucl Med Mol Imaging. 2021; 48: 4115-4117.
  6. Kao YH. Single time point tumour dosimetry assuming normal distribution of tumour kinetics. J Nucl Med. 2022; 63:803.
  7. Lassmann M, Hanscheid H, Chiesa C, Hindorf C, Flux G, Luster M. EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy. Eur J Nucl Med Mol Imaging. 2008; 35: 1405-1412.
  8. Hanscheid H, Lassman M, Luster M, Kloos RT, Reiners C. Blood dosimetry from a single measurement of the whole body radioiodine retention in patients with differentiated thyroid carcinoma. Endocr Relat Cancer. 2009; 16: 1283-1289.
  9. Thomas SR, Samaratunga RC, Sperling M, Maxon HR. Predictive estimate of blood dose from external counting data preceding radioiodine therapy for thyroid cancer. Nucl Med Biol. 1993; 20: 157-162.
  10. Benua RS, Cicale NR, Sonenberg M, Rawson RW. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am J Roentgenol Radium Ther Nucl Med. 1962; 87: 171-182.
  11. Song H, He B, Prideaux A, Du Y, Frey E, Kasecamp W, et al. Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases. J Nucl Med. 2006; 47: 1985-1994.
  12. Kao YH. Letter to the editor: Radioiodine is molecular radiotherapy governed by predictable deterministic radiobiology expressed in gray, not millicuries. Thyroid. 2022; 32:340-341.
آمار
تعداد مشاهده مقاله: 696
تعداد دریافت فایل اصل مقاله: 448